-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, H0tAHJ2K3qJIAx4BIi4gIerkwk7sP+rbzy1CzEwLYxw+rg2wrrqa45oxhwd4IKn4 vr/7SDZD4Ngz8GoCCrxqWg== 0000930413-10-001405.txt : 20100312 0000930413-10-001405.hdr.sgml : 20100312 20100312161922 ACCESSION NUMBER: 0000930413-10-001405 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20100312 DATE AS OF CHANGE: 20100312 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GREAT POINT PARTNERS LLC CENTRAL INDEX KEY: 0001281446 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G MAIL ADDRESS: STREET 1: 2 PICKWICK PLAZA STREET 2: STE 450 CITY: GREENWICH STATE: CT ZIP: 06830 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS INC CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-83043 FILM NUMBER: 10678002 BUSINESS ADDRESS: STREET 1: 6 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: (609) 662-2000 MAIL ADDRESS: STREET 1: 6 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 SC 13G 1 c60605_13g.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Schedule 13G

 

 
         

 

Under the Securities Exchange Act of 1934

 

 
         

 

(Amendment No.  )*

 

 

 

 

 

 

 

 

 

   

 

Amicus Therapeutics, Inc.

 

(Name of Issuer)

 

Common Stock

 

(Title of Class of Securities)

 

03152W109

 

(CUSIP Number)

 

March 2, 2010

 

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:


 

 

o

Rule 13d-1(b)

 

 

x

Rule 13d-1(c)

 

 

o

Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

1



 

 

 

CUSIP No. 03152W109

13G

Page 2 of 12 Pages


 

 

 

   1.

NAMES OF REPORTING PERSONS

 

Great Point Partners, LLC

 

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

 

37-1475292

   2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a)

o

 

 

 

 

(b)

o

 

 

 

 

 

 

   3.

SEC USE ONLY

 

 

 

 

 

 

 

 

 

   4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

USA

 


 

 

 

 

 

 

NUMBER OF SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH

 

5.

SOLE VOTING POWER

 

 

 

0

 

 

6.

SHARED VOTING POWER

 

 

 

2,742,0231

 

 

7.

SOLE DISPOSITIVE POWER

 

 

 

 

0

 

 

8.

SHARED DISPOSITIVE POWER

 

 

 

2,742,0231

 


 

 

 

   9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

          2,742,0231

 


 

 

1

Consists of 671,555 shares owned by Biomedical Value Fund, LP (“BVF”), 742,687 shares owned by Biomedical Offshore Value Fund, Ltd. (“BOVF”), 258,269 shares owned by Biomedical Institutional Value Fund, LP (“BIVF”), 401,064 shares owned by Lyrical Multi-Manager Fund, LP (“Lyrical”) and 668,448 shares owned by Class D Series of GEF-PS, LP (“GEF-PS”). Does not include 234,612 shares underlying a warrant held by BVF, 254,700 shares underlying a warrant held by BOVF, 87,228 shares underlying a warrant held by BIVF, 150,399 shares underlying a warrant held by Lyrical and 250,668 shares underlying a warrant held by GEF-PS. The warrants are not exercisable until September 2, 2010. As a result, the reporting persons disclaim beneficial ownership of the shares underlying the warrants until 60 days prior to such date. In addition, the provisions of such warrants restrict the exercise of such warrants to the extent that, after giving effect to such exercise, the holder of the warrants and its affiliates and any other person or entities with which such holder would constitute a group would beneficially own in excess of 9.9% of the number of shares of Common Stock of the Issuer outstanding immediately after giving effect to such exercise (the “Ownership Cap”). Accordingly, sixty days prior to the warrants becoming exercisable, the reporting persons may be deemed to become the beneficial owners of such additional number of shares underlying such warrants, which together with the shares currently owned, would result in beneficial ownership by the reporting persons of such number of shares equal to the Ownership Cap.



 

 

 

CUSIP No. 03152W109

13G

Page 3 of 12 Pages


  10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

o

 

 

 

  11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

          9.94%1,2

 

  12.

TYPE OF REPORTING PERSON (See Instructions)

 

 

          OO

 


 

 

2

Based on a total of 27,594,393 shares outstanding, calculated as follows: 22,647,869 shares outstanding as reported in the Issuer’s 10-Q for the quarter ended September 30, 2009, plus an additional 4,946,524 shares issued by the Issuer pursuant to a private placement as reported by the Issuer on a Form 8-K filed on February 26, 2010.




 

 

 

CUSIP No. 03152W109

13G

Page 4 of 12 Pages


 

 

 

   1.

NAMES OF REPORTING PERSONS

 

Dr. Jeffrey R. Jay, M.D.

 

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

 

 

 

   2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a)

o

 

 

 

 

(b)

o

 

 

 

 

 

 

   3.

SEC USE ONLY

 

 

 

 

 

 

 

 

 

   4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

USA

 


 

 

 

 

 

 

NUMBER OF SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH

 

5.

SOLE VOTING POWER

 

 

 

0

 

 

6.

SHARED VOTING POWER

 

 

 

2,742,0231

 

 

7.

SOLE DISPOSITIVE POWER

 

 

 

 

0

 

 

8.

SHARED DISPOSITIVE POWER

 

 

 

2,742,0231

 


 

 

 

   9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

          2,742,0231

 

  10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

o

 

 

 

  11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

          9.94%1,2

 

  12.

TYPE OF REPORTING PERSON (See Instructions)

 

 

          IN

 




 

 

 

CUSIP No. 03152W109

13G

Page 5 of 12 Pages


 

 

 

   1.

NAMES OF REPORTING PERSONS

 

Mr. David Kroin

 

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

 

 

 

   2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a)

o

 

 

 

 

(b)

o

 

 

 

 

 

 

   3.

SEC USE ONLY

 

 

 

 

 

 

 

 

 

   4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

USA

 


 

 

 

 

 

 

NUMBER OF SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH

 

5.

SOLE VOTING POWER

 

 

 

0

 

 

6.

SHARED VOTING POWER

 

 

 

2,742,0231

 

 

7.

SOLE DISPOSITIVE POWER

 

 

 

 

0

 

 

8.

SHARED DISPOSITIVE POWER

 

 

 

2,742,0231

 


 

 

 

   9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

          2,742,0231

 

  10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

o

 

 

 

  11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

          9.94%1,2

 

  12.

TYPE OF REPORTING PERSON (See Instructions)

 

 

          IN

 




 

 

 

CUSIP No. 03152W109

13G

Page 6 of 12 Pages


 

 

 

 

 

Item 1.

 

 

 

 

 

 

 

 

(a)

Name of Issuer

 

 

 

 

 

Amicus Therapeutics, Inc.

 

 

 

 

(b)

Address of Issuer’s Principal Executive Offices

 

 

 

 

 

6 Cedar Brook Drive, Cranbury, NJ 08512

 

 

 

Item 2.

 

 

 

 

 

(a)

Name of Person Filing

 

 

 

 

 

 

 

Great Point Partners, LLC
Dr. Jeffrey R. Jay, M.D.
Mr. David Kroin

 

 

 

 

 

The Reporting Persons have entered into a Joint Filing Agreement, dated March 12, 2010, a copy of which is filed with this Schedule 13G as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

 

 

(b)

Address of Principal Business Office, or if none, Residence

 

 

 

 

 

The address of the principal business office of each of the Reporting Persons is

 

 

 

 

 

 

165 Mason Street, 3rd Floor
Greenwich, CT 06830

 

 

 

 

 

(c)

Citizenship

 

 

 

 

 

Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Mr. David Kroin is a citizen of the United States.

 

 

 

(d)

Title of Class of Securities

 

 

 

 

 

Common Stock

 

 

 

 

(e)

CUSIP Number

 

 

 

 

 

03152W109

 

 

 

Item 3.

If this statement is filed pursuant to §240.13d-1(b) or 240.13d.2(b) or (c), check whether the person filing is a:

 

 

 

 

Not Applicable.


 

 

 

 

 

(a)

o

Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o)

 

 

 

 

 

(b)

o

Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

 

 

 

 

 

(c)

o

Insurance company as defined in Section 3(a)(19) of the Act (15. U.S.C. 78c).

 

 

 

 

 

(d)

o

Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

 

 

 

 

 

(e)

o

An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).




 

 

 

CUSIP No. 03152W109

13G

Page 7 of 12 Pages


 

 

 

 

 

(f)

o

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

 

 

 

 

 

(g)

o

A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).

 

 

 

 

 

(h)

o

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

 

 

 

 

 

(i)

o

A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

 

 

 

 

 

(j)

o

Group, in accordance with §240.13d-1(b)(1)(ii)(J).

 

 

 

 

Item 4.

Ownership

 

 

 

Biomedical Value Fund, L.P. (“BVF”) is the record owner of 671,555 shares of Common Stock (the “BVF Shares”). Great Point Partners, LLC (“Great Point”) is the investment manager of BVF, and by virtue of such status may be deemed to be the beneficial owner of the BVF Shares. Each of Dr. Jeffrey R. Jay, M.D. (“Dr. Jay”), as senior managing member of Great Point, and Mr. David Kroin (“Mr. Kroin”), as special managing member of Great Point, has voting and investment power with respect to the BVF Shares, and therefore may be deemed to be the beneficial owner of the BVF Shares. In addition, BVF is the record owner of a warrant to purchase 234,612 shares.

 

 

 

Biomedical Offshore Value Fund, Ltd. (“BOVF”) is the record owner of 742,687 shares of Common Stock (the “BOVF Shares”). Great Point is the investment manager of BOVF, and by virtue of such status may be deemed to be the beneficial owner of the BOVF Shares. Each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the BOVF Shares, and therefore may be deemed to be the beneficial owner of the BOVF Shares. In addition, BOVF is the record owner of a warrant to purchase 254,700 shares.

 

 

 

Biomedical Institutional Value Fund, L.P. (“BIVF”) is the record owner of 258,269 shares of Common Stock (the “BIVF Shares”). Great Point is the investment manager of BIVF, and by virtue of such status may be deemed to be the beneficial owner of the BIVF Shares. Each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the BIVF Shares, and therefore may be deemed to be the beneficial owner of the BIVF Shares. In addition, BIVF is the record owner of a warrant to purchase 87,228 shares.

 

 

 

Lyrical Multi-Manager Fund, LP (“Lyrical”) is the record owner of 401,064 shares of Common Stock (the “Lyrical Shares”). Great Point is the investment manager of Lyrical, and by virtue of such status may be deemed to be the beneficial owner of the Lyrical Shares. Each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the Lyrical Shares, and therefore may be deemed to be the beneficial owner of the Lyrical Shares. In addition, Lyrical is the record owner of a warrant to purchase 150,399 shares.

 

 

 

Class D Series of GEF-PS, LP (“GEF-PS”) is the record owner of 668,448 shares of Common Stock (the “GEF-PS Shares”). Great Point is the investment manager of GEF-PS, and by virtue of such status may be deemed to be the beneficial owner of the GEF-PS Shares. Each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the GEF-PS Shares, and therefore may be deemed to be the beneficial owner of the GEF-PS Shares. In addition, GEF-PS is the record owner of a warrant to purchase 250,668 shares.




 

 

 

CUSIP No. 03152W109

13G

Page 8 of 12 Pages


 

 

 

 

 

The warrants described above are not exercisable until September 2, 2010. As a result, the reporting persons disclaim beneficial ownership of the shares underlying the warrants until 60 days prior to such date. In addition, the provisions of such warrants restrict the exercise of such warrants to the extent that, after giving effect to such exercise, the holder of the warrants and its affiliates and any other person or entities with which such holder would constitute a group would beneficially own in excess of 9.9% of the number of shares of Common Stock of the Issuer outstanding immediately after giving effect to such exercise (the “Ownership Cap”). Accordingly, sixty days prior to the warrants becoming exercisable, the reporting persons may be deemed to become the beneficial owners of such additional number of shares underlying such warrants, which together with the shares currently owned, would result in beneficial ownership by the reporting persons of such number of shares equal to the Ownership Cap.

 

 

 

Notwithstanding the above, Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of the BVF Shares, the BOVF Shares, the BIVF Shares, the Lyrical Shares, the GEF-PS Shares and the shares underlying the warrants described above, except to the extent of their respective pecuniary interests.

 

 

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.


 

 

 

 

 

1.

Great Point Partners, LLC

 

 

 

 

(a)

Amount beneficially owned: 2,742,0233

 

 

 

 

(b)

Percent of class: 9.94%3, 4

 

 

 

 

(c)

Number of shares as to which the person has:


 

 

3

Consists of 671,555 shares owned by Biomedical Value Fund, LP (“BVF”), 742,687 shares owned by Biomedical Offshore Value Fund, Ltd. (“BOVF”), 258,269 shares owned by Biomedical Institutional Value Fund, LP (“BIVF”), 401,064 shares owned by Lyrical Multi-Manager Fund, LP (“Lyrical”) and 668,448 shares owned by Class D Series of GEF-PS, LP (“GEF-PS”). Does not include 234,612 shares underlying a warrant held by BVF, 254,700 shares underlying a warrant held by BOVF, 87,228 shares underlying a warrant held by BIFV, 150,399 shares underlying a warrant held by Lyrical and 250,668 shares underlying a warrant held by GEF-PS. The warrants are not exercisable until September 2, 2010. As a result, the reporting persons disclaim beneficial ownership of the shares underlying the warrants until 60 days prior to such date. In addition, the provisions of such warrants restrict the exercise of such warrants to the extent that, after giving effect to such exercise, the holder of the warrants and its affiliates and any other person or entities with which such holder would constitute a group would beneficially own in excess of 9.9% of the number of shares of Common Stock of the Issuer outstanding immediately after giving effect to such exercise (the “Ownership Cap”). Accordingly, sixty days prior to the warrants becoming exercisable, the reporting persons may be deemed to become the beneficial owners of such additional number of shares underlying such warrants, which together with the shares currently owned, would result in beneficial ownership by the reporting persons of such number of shares equal to the Ownership Cap.

 

 

4

Based on a total of 27,594,393 shares outstanding, calculated as follows: 22,647,869 shares outstanding as reported in the Issuer’s 10-Q for the quarter ended September 30, 2009, plus an additional 4,946,524 shares issued by the Issuer pursuant to a private placement as reported by the Issuer on a Form 8-K filed on February 26, 2010.




 

 

 

CUSIP No. 03152W109

13G

Page 9 of 12 Pages


 

 

 

 

 

 

(i)

Sole power to vote or to direct the vote: - 0 -

 

 

 

 

 

 

(ii)

Shared power to vote or to direct the vote: 2,742,0233

 

 

 

 

 

 

(iii)

Sole power to dispose or to direct the disposition of: - 0 -.

 

 

 

 

 

 

(iv)

Shared power to dispose or to direct the disposition of: 2,742,0233

 

 

 

 

 

2.

Dr. Jeffrey R. Jay, M.D.

 

 

 

 

 

(a)

Amount beneficially owned: 2,742,0233

 

 

 

 

 

(b)

Percent of class: 9.94%3,4

 

 

 

 

 

(c)

Number of shares as to which the person has:

 

 

 

 

 

 

(i)

Sole power to vote or to direct the vote: 0.

 

 

 

 

 

 

(ii)

Shared power to vote or to direct the vote: 2,742,0233

 

 

 

 

 

 

(iii)

Sole power to dispose or to direct the disposition of: 0.

 

 

 

 

 

 

(iv)

Shared power to dispose or to direct the disposition of: 2,742,0233

 

 

 

 

 

3.

Mr. David Kroin

 

 

 

 

 

(a)

Amount beneficially owned: 2,742,0233

 

 

 

 

 

(b)

Percent of class: 9.94%3,4

 

 

 

 

 

(c)

Number of shares as to which the person has:

 

 

 

 

 

 

(i)

Sole power to vote or to direct the vote: 0.

 

 

 

 

 

 

(ii)

Shared power to vote or to direct the vote: 2,742,0233

 

 

 

 

 

 

(iii)

Sole power to dispose or to direct the disposition of: 0.

 

 

 

 

 

 

(iv)

Shared power to dispose or to direct the disposition of: 2,742,0233

 

 

 

 

Item 5.

Ownership of Five Percent or Less of a Class

 

 

 

 

                   If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

 

 

 

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person:

 

 

 

 

 

See Item 4.

 

 

 

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company


 

 

 

Not Applicable.

 

 

Item 8.

Identification and Classification of Members of the Group

 

 

 

Not Applicable.




 

 

 

CUSIP No. 03152W109

13G

Page 10 of 12 Pages


 

 

Item 9.

Notice of Dissolution of Group

 

 

 

Not Applicable.

 

 

Item 10.

Certification

 

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as participant in any transaction having that purpose or effect.




 

 

 

CUSIP No. 03152W109

13G

Page 11 of 12 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: March 12, 2010

 

 

 

 

 

GREAT POINT PARTNERS, LLC

 

 

 

By:

/s/ Dr. Jeffrey R. Jay, M.D.

 

 

 

 

 

 

 

Dr. Jeffrey R. Jay, M.D.,
  as senior managing member

 

 

 

 

 

 

/s/ Dr. Jeffrey R. Jay, M.D.

 

 

 

 

 

DR. JEFFREY R. JAY, M.D.

 

 

 

 

 

 

/s/ Mr. David Kroin

 

 

 

 

 

MR. DAVID KROIN

 



Exhibit A

AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G

The undersigned hereby agree as follows:

          (i)           Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and

          (ii)           Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

Date: March 12, 2010

 

 

 

 

 

GREAT POINT PARTNERS, LLC

 

 

 

By:

/s/ Dr. Jeffrey R. Jay, M.D.

 

 

 

 

 

 

 

Dr. Jeffrey R. Jay, M.D.,
  as senior managing member

 

 

 

 

 

 

/s/ Dr. Jeffrey R. Jay, M.D.

 

 

 

 

 

DR. JEFFREY R. JAY, M.D.

 

 

 

 

 

/s/ Mr. David Kroin

 

 

 

 

 

MR. DAVID KROIN

 



-----END PRIVACY-ENHANCED MESSAGE-----